COMPANY NEWS


Alembic Pharmaceuticals Ltd
BSE Code 533573 ISIN Demat INE901L01018 Book Value (₹) 249.74 NSE Symbol APLLTD Div & Yield % 1.1 Market Cap ( Cr.) 19,718.23 P/E * 29.58 EPS * 33.91 Face Value (₹) 2
* Profit to Earning Ratio
* Earning Per Share
Alembic Pharmaceuticals receives USFDA tentative approval for Ribociclib Tablets Back
(01 Apr 2024)
Alembic Pharmaceuticals has received US Food & Drug administration (USFDA) Product Approval (Tentative) for Ribociclib Tablets, 200 mg.

Ribociclib tablet indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy.

Alembic has a cumulative total of 197 ANDA approvals (170 final approvals and 27 tentative approvals) from USFDA.